Business Insider

Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate ...

--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE ® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of ...
News Medical

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) ...
Nasdaq

Teva Stock Falls as Novartis Brings Another Copaxone Generic

Shares of Teva Pharmaceutical Industries LimitedTEVA were down around 4% on Tuesday, as another generic version of its blockbuster multiple sclerosis injection, Copaxone was launched earlier than ...
Business Insider

Mylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and ...

HERTFORDSHIRE, England, and PITTSBURGH, Oct. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the company has launched in the U.S. the first Glatiramer Acetate Injection 40 ...
Pharmabiz

Teva gets Russian marketing nod for thrice a week Copaxone 40 mg/ml for RRMS treatment

Teva Pharmaceutical Industries Ltd announced that the Russian Ministry of Health has approved the Marketing Authorisation (MA) license for three-times-a-week Copaxone (glatiramer acetate injection) 40 ...
FiercePharma

New Formulation of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less ...

JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental ...
Nasdaq

Mylan, Synthon Win European Patent Office Ruling Related To Copaxone 40 Mg/ML

(RTTNews) - Mylan N.V. (MYL) said Tuesday that the company and development partner Synthon has won a significant European Patent Office ruling related to Copaxone 40 mg/mL. According to Mylan, the ...
FierceBiotech

Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with ...

<0> Teva Pharmaceutical Industries Ltd.IR:United States 215-591-8912or215-591-3033orIsrael 972 (3) 926-7656orPR:Israel 972 (3) 926-7687orUnited States 215-591-8974or215-284-0213 </0> Teva ...
The Providence Journal

Mylan's ANDA for Three Times Per Week Generic Copaxone(R) 40 mg/mL Accepted for Filing by FDA

PITTSBURGH, Aug. 28, 2014 /PRNewswire/ -- Mylan Inc. today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted ...
FiercePharma

Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer ...

<0> Teva Pharmaceutical Industries Ltd.IR:United States, 215-591-8912, 215-591-3033orIsrael, 972 (3) 926-7656orPR:Israel, 972 (3) 926-7687orUnited States, 215-591-8974, 215-284-0213 </0> Teva ...
Business Wire

Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent ...
JD Supra

Invalidity Of Copaxone Patents Supported By Statements To FDA

In In re Copaxone Consolidated Cases, the Federal Circuit affirmed the district court decision finding four patents directed to a specific dosing regimen for using COPAXONE® 40 mg/ml to treat patients ...